Jeffrey S. Ross on Muck Rack

Jeffrey S. Ross

As seen in: Expert Review of Molecular Diagnostics, Color Research & Application, Nature, The Oncologist, Journal of Clinical Pathology, JAMA (The Journal of the American Medical Association), JAMA Oncology, The Sun (San Bernardino, CA), Inland Valley Daily Bulletin, Redlands Daily Facts, European Urology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jeffrey S.

Contact Jeffrey S., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ultra-high tumor mutation burden breast cancer: genomic profiling and real-world immunotherapy results

|
By Kristina Fanucci, Mariya Rozenblit, Julia C. F. Quintanilha, Ryon P. Graf, Neal Fischbach, Prashanth Kumar, Ethan S Sokol, Smruthy Sivakumar, Dean Pavlick, Jeffrey S. Ross, Maryam B. Lustberg, Lajos Pusztai, Maureen Pelletier, Abirami Sivapiragasam, Mansi Kallem
| Nature Verified
Abstract Patients with metastatic breast cancer and tumor mutational burden (TMB) ≥10 mutations/megabase are eligible for immunotherapy, but clinical and genomic characteristics and outcomes of patients with ultra-high TMB (UHTMB) ≥20 mutations/megabase remain under-characterized. In this retrospective cohort and comparative effectiveness study we examined comprehensive genomic profiling assessed on tumors as part of routine care.
Open in Who Shared Issue with article?

FGFR Inhibition in Urothelial Carcinoma

|
By Roger Li, Joshua A. Linscott, James Catto, Joshua J. Meeks, Siamak Daneshmand, Bishoy M Faltas, Ashish M. Kamat, Andrea Necchi, Benjamin Pradere, Jeffrey S. Ross
| European Urology Verified
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA bDepartment of Immunology, H.
Open in Who Shared Issue with article?

Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross

|
By Jeffrey S. Ross
| UroToday Verified
Read the Full Video Transcript Ashish Kamat: Hello, and welcome to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, Professor of Urologic Oncology at MD Anderson Cancer Center and it's a distinct pleasure to invite and welcome and have here today Professor Jeffrey Ross who's going to talk to us about micropapillary urothelial carcinoma. Dr. Ross really needs no introduction to most of us.
Open in Who Shared Issue with article?
See all 20 licensed articles (22 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified